NeoGenomics Announces NASDAQ Capital Market Listing

             NeoGenomics Announces NASDAQ Capital Market Listing

PR Newswire

FT. MYERS, Fla., Dec. 6, 2012

FT. MYERS, Fla., Dec. 6, 2012 /PRNewswire/ --NeoGenomics, Inc. (OTC-BB:NGNM),
a leading provider of cancer-focused genetic testing services, announced today
that its common stock has been approved for listing on the NASDAQ Capital

The company expects to commence trading on the NASDAQ Capital Market on
Monday, December 10, 2012 under the ticker symbol "NEO". Prior to the listing
change to NASDAQ, the company's common stock will continue to trade on the OTC
Bulletin Board under the current ticker symbol "NGNM".

Douglas VanOort, the company's Chairman and CEO, commented, "The transition to
the NASDAQ Capital Market is a significant milestone for NeoGenomics and
reflects the strong revenue and operating income growth we have achieved over
the last several years.We believe this move will increase the visibility and
liquidity of our shares in the market, and we are honored to join the long
list of prestigious companies already traded on NASDAQ." 

In honor of the transition to NASDAQ, Douglas VanOort, Chairman and CEO, and
other NeoGenomics colleagues will ring the closing bell at The NASDAQ Stock
Market in Times Square in New York on Thursday, December 13th.

About NeoGenomics, Inc.

NeoGenomics, Inc. is a high-complexity CLIA–certified clinical laboratory that
specializes in cancer genetics testing, the fastest growing segment of the
laboratory industry. The company's testing services include cytogenetics,
fluorescence in-situ hybridization (FISH), flow cytometry,
immunohistochemistry, morphology studies, anatomic pathology and molecular
genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in
Nashville, TN, Irvine, CA, Tampa, FL and Fort Myers, FL. NeoGenomics services
the needs of pathologists, oncologists, urologists and other clinicians, and
hospitals throughout the United States. For additional information about
NeoGenomics, visit

Forward Looking Statements

Except for historical information, all of the statements, expectations and
assumptions contained in the foregoing are forward-looking statements. These
forward looking statements involve a number of risks and uncertainties that
could cause actual future results to differ materially from those anticipated
in the forward looking statements. Actual results could differ materially
from such statements expressed or implied herein. Factors that might cause
such a difference include, among others, the company's ability to continue
gaining new customers, offer new types of tests, and otherwise implement its
business plan. As a result, this press release should be read in conjunction
with the company's periodic filings with the SEC.

SOURCE NeoGenomics, Inc.

Contact: Steven C. Jones, NeoGenomics, Inc., Director of Investor Relations,
+1-239-325-2001,; or Ms. Julie Marshall, Hawk
Associates, Inc., +1-305-451-1888,
Press spacebar to pause and continue. Press esc to stop.